Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

NCT05223816 is registered in ClinicalTrials.gov with Virogin Biotech Canada Ltd as lead sponsor.

NCT NCT05223816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05223816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Lead sponsor
Virogin Biotech Canada Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
January 24, 2024
Completion date
December 31, 2025
Enrollment
97 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, intrahepatic cholangiocarcinoma